Matches in SemOpenAlex for { <https://semopenalex.org/work/W4241148474> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4241148474 endingPage "654" @default.
- W4241148474 startingPage "653" @default.
- W4241148474 abstract "Treatment of essential hypertension. Aliskiren is the first renin inhibitor to be licensed in Europe. It selectively inhibits renin, the first enzyme in the renin–angiotensin system (RAS) cascade, thereby inhibiting the formation of angiotensin I from angiotensinogen (Figure 1). This reduces the production of vasoconstrictor angiotensin II and mineralocorticoid aldosterone, resulting in vasodilation, decreased sympathetic activity and increased excretion of sodium ions by the kidneys with a consequent decrease in blood pressure. Aliskiren inhibits the activity of the enzyme renin at the onset of the conversion cascade within the renin–angiotensin system (RAS), eventually resulting in a decrease in blood pressure. ACE, angiotensin converting enzyme; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; AT-R, angiotensin-II receptor Other antihypertensive drugs, such as angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone antagonists exert their actions at later stages in the system. All drugs that block the RAS inhibit the negative feedback of angiotensin II on renin secretion, leading to a compensatory rise in renin concentration. Aliskiren is special because it inhibits the RAS at its origin. Furthermore, in contrast to other RAS-blocking agents, aliskiren decreases plasma renin activity despite the compensatory rise in renin concentration. Aliskiren does not interfere with the degradation of bradykinin (which is inhibited by angiotensin converting enzyme inhibitors but not by angiotensin receptor blockers). Aliskiren causes only mild and transient adverse reactions, of which diarrhoea is the most common. Peripheral oedema, rash, and influenza-like symptoms have been reported. Siragy HM, Kar S, Kirkpatrick P. Fresh from the pipeline: Aliskiren. Nat Rev Drug Discov 2007; 6: 779–80. Available at http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm" @default.
- W4241148474 created "2022-05-12" @default.
- W4241148474 creator A5037445211 @default.
- W4241148474 creator A5047227576 @default.
- W4241148474 date "2009-11-01" @default.
- W4241148474 modified "2023-09-25" @default.
- W4241148474 title "Aliskiren" @default.
- W4241148474 doi "https://doi.org/10.1111/j.1365-2125.2009.03504.x" @default.
- W4241148474 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19916988" @default.
- W4241148474 hasPublicationYear "2009" @default.
- W4241148474 type Work @default.
- W4241148474 citedByCount "2" @default.
- W4241148474 countsByYear W42411484742014 @default.
- W4241148474 crossrefType "journal-article" @default.
- W4241148474 hasAuthorship W4241148474A5037445211 @default.
- W4241148474 hasAuthorship W4241148474A5047227576 @default.
- W4241148474 hasBestOaLocation W42411484742 @default.
- W4241148474 hasConcept C104849204 @default.
- W4241148474 hasConcept C123915805 @default.
- W4241148474 hasConcept C126322002 @default.
- W4241148474 hasConcept C134018914 @default.
- W4241148474 hasConcept C138976137 @default.
- W4241148474 hasConcept C170493617 @default.
- W4241148474 hasConcept C185592680 @default.
- W4241148474 hasConcept C198710026 @default.
- W4241148474 hasConcept C27016395 @default.
- W4241148474 hasConcept C2777425892 @default.
- W4241148474 hasConcept C2778525890 @default.
- W4241148474 hasConcept C2779591629 @default.
- W4241148474 hasConcept C2779838083 @default.
- W4241148474 hasConcept C2908929049 @default.
- W4241148474 hasConcept C71924100 @default.
- W4241148474 hasConcept C84393581 @default.
- W4241148474 hasConcept C98274493 @default.
- W4241148474 hasConceptScore W4241148474C104849204 @default.
- W4241148474 hasConceptScore W4241148474C123915805 @default.
- W4241148474 hasConceptScore W4241148474C126322002 @default.
- W4241148474 hasConceptScore W4241148474C134018914 @default.
- W4241148474 hasConceptScore W4241148474C138976137 @default.
- W4241148474 hasConceptScore W4241148474C170493617 @default.
- W4241148474 hasConceptScore W4241148474C185592680 @default.
- W4241148474 hasConceptScore W4241148474C198710026 @default.
- W4241148474 hasConceptScore W4241148474C27016395 @default.
- W4241148474 hasConceptScore W4241148474C2777425892 @default.
- W4241148474 hasConceptScore W4241148474C2778525890 @default.
- W4241148474 hasConceptScore W4241148474C2779591629 @default.
- W4241148474 hasConceptScore W4241148474C2779838083 @default.
- W4241148474 hasConceptScore W4241148474C2908929049 @default.
- W4241148474 hasConceptScore W4241148474C71924100 @default.
- W4241148474 hasConceptScore W4241148474C84393581 @default.
- W4241148474 hasConceptScore W4241148474C98274493 @default.
- W4241148474 hasIssue "5" @default.
- W4241148474 hasLocation W42411484741 @default.
- W4241148474 hasLocation W42411484742 @default.
- W4241148474 hasLocation W42411484743 @default.
- W4241148474 hasLocation W42411484744 @default.
- W4241148474 hasOpenAccess W4241148474 @default.
- W4241148474 hasPrimaryLocation W42411484741 @default.
- W4241148474 hasRelatedWork W1966128948 @default.
- W4241148474 hasRelatedWork W2024736606 @default.
- W4241148474 hasRelatedWork W2056418138 @default.
- W4241148474 hasRelatedWork W2077998387 @default.
- W4241148474 hasRelatedWork W2118736985 @default.
- W4241148474 hasRelatedWork W2126797993 @default.
- W4241148474 hasRelatedWork W2132612653 @default.
- W4241148474 hasRelatedWork W2149410839 @default.
- W4241148474 hasRelatedWork W2795831384 @default.
- W4241148474 hasRelatedWork W4247631657 @default.
- W4241148474 hasVolume "68" @default.
- W4241148474 isParatext "false" @default.
- W4241148474 isRetracted "false" @default.
- W4241148474 workType "article" @default.